World Cancer Day

Ged Killen Excerpts

Wednesday 30th January 2019 Westminster Hall

[John Lamont]

I am grateful to the hon. Lady for making that point. There is a range of options that we need to consider. I recently met my local NHS health board, and I meet a number of my GPs frequently. There are vacancies in all different parts of the health service, and we need to consider how we get more people in to do the jobs that we need. There is a particular challenge in my constituency—many rural communities do not have enough GPs or get enough nurses. Bursaries may be part of that. There are a range of things that we need to do, and that the Scottish Government and the UK Government can do, to address those issues.

For example, there is a 10% vacancy rate for radiology consultants across Scotland. One in five of the current workforce are expected to retire over the next five years. So, yes, there are challenges just now, but there are future challenges coming down the line.

[Ged Killen (Rutherglen and Hamilton West) (Lab/Co-op)]

I congratulate the hon. Gentleman on securing the debate. He talks about access to existing treatments, but does he agree that more work has to be done on conditions for which treatment is not yet available? The late Tessa Jowell worked very hard on this issue, right up to the end of her life, trying to improve access to new treatments and to improve care for people with conditions for which there is perhaps no treatment out there. Does he agree that we should pay tribute to Tessa Jowell and continue that work?

[John Lamont]

I absolutely agree. We need to do much more to promote awareness of those conditions. I will come on later to the availability of drugs.

The Scottish Government recognise that the high number of vacancies is a problem, but missed their target for increasing the number of nurse endoscopists by 40%. In England, nurse vacancies are similarly too high. The availability of drugs is also an issue that concerns charities and patients alike. The most high-profile example is the breast cancer drug Perjeta, which was rejected for use three times in Scotland but was finally approved just a few weeks ago. Quicker and more cost-effective access to the latest and best treatments must be a priority in future.

I know that colleagues will want to press the Minister on what the UK Government are doing to tackle cancer in England, but all these issues need to be addressed across all parts of our United Kingdom. As a Scottish MP, I am conscious that the Minister is not directly responsible for the cancer waiting times and treatments for my constituents. However, UK-wide approaches should be taken to help us tackle cancer head on, together.

World Cancer Day is all about recognising that cancer knows no boundaries, and that individual Governments cannot address these challenges in isolation. That gives rise to the question: are the UK Government and devolved Governments working as well together on this issue as they should be? For example, should we buy some drugs and equipment on a UK-wide basis? Current practice is that four separate bodies approve new drugs across the UK. While that allows different parts of the UK to make their own decisions, surely a UK-wide approach would make sense in some cases. We could make ultra-orphan drugs more affordable or use economies of scale to deliver common drugs at lower cost.

I am therefore interested in the Minister’s views on this suggestion. Have there been any discussions with the devolved Administrations about this possibility? Are health boards across the UK as good as they can be at talking to each other and sharing best practice? Representing a constituency on the border with England, I all too often see examples of that border acting as a barrier to co-operation. I certainly hope that that is not the case when it comes to cancer treatment.

I hugely welcome the extra funding coming the NHS’s way, which will of course mean an extra £2 billion a year for the Scottish Government to spend on health, if they choose. Will the Minister outline what that means for cancer treatment in England, and how much of that extra funding will be used to improve treatment and reduce cancer waiting times?

Can we do more to support families with the cost of cancer treatment? Parents spend an average £600 a month in additional expenses as a result of their child’s active cancer treatment, much of that on travel costs. Young people in my constituency often have to make a 100-mile round trip to Edinburgh for tests and treatment. Children’s cancer charity CLIC Sargent is calling for a cancer patient travel fund, as well as a review of the disability living allowance and personal independence payments, to backdate young cancer patients’ financial support to their day of diagnosis. I certainly think that these are reasonable suggestions.